Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents.

Leukemia research - 1 Mar 1998

Banker D E, Groudine M, Willman C L, Norwood T, Appelbaum F R

Abstract excerpt

Cell cycle checkpoints establish the timing and strength of arrest, repair and apoptosis responses to damaging treatments. We designed flow cytometric assays to measure cell cycle arrest and apoptosis in acute myeloid leukemia (AML) samples treated in vitro with relevant therapeutic agents so as to functionally characterize checkpoints in these samples and to ask if checkpoint abnormalities are common in AML and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Flow Cytometry

Share to Genes, p53

Share to Karyotyping

Share to Mutation

Share to Reproducibility of Results

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 9619914
DOI: 10.1016/s0145-2126(97)00174-4

Genes

PCNA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents.PMID 9619914Read ↗

Immunophenotypic analysis of cell cycle status in acute myeloid leukaemia: relationship to cytogenetics, genotype and clinical outcome.Semantic proximity Read ↗

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell LinesSemantic proximity Read ↗

Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cellsSemantic proximity Read ↗

Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy.Semantic proximity Read ↗

The cell cycle checkpoint inhibitors in the treatment of leukemiasSemantic proximity Read ↗

Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients.Semantic proximity Read ↗

CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated CytotoxicitySemantic proximity Read ↗

Cell differentiation in acute myeloid leukemiaSemantic proximity Read ↗

Impaired S-phase arrest in acute myeloid leukemia cells with a FLT3 internal tandem duplication treated with clofarabine.Semantic proximity Read ↗

DNMT3A harboring leukemia-associated mutations directs sensitivity to DNA damage at replication forksSemantic proximity Read ↗

Identification of a subset of patients with acute myeloid leukemia characterized by long-term<i>in vitro</i>proliferation and altered cell cycle regulation of the leukemic cellsSemantic proximity Read ↗

Rigosertib induces cell death of a myelodysplastic syndrome‐derived cell line by <scp>DNA</scp> damage‐induced G2/M arrestSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.